Clinical Trial Update: A 24-week Evaluation of GSK573719/Vilanterol (62.5/25mcg) and Components in COPD [Phase 3]

View source ↗

Summary

A 24-week Phase 3 trial evaluating GSK573719/vilanterol and components in COPD has completed with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• GSK573719/vilanterol

Snippet

Sponsor: GlaxoSmithKline | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 3 | Status: COMPLETED | Results posted: 2014-03-04